

#AAD2019

*Highlights*  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Scientific Initiative of:



Sponsored by:



#AAD2019

*Highlights*  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

Psoriasis

Dra. Mar Llamas-Velasco

Scientific Initiative of:



Sponsored by:





# FRIDAY 1ST OF MARCH



- S003 NEW EMERGING THERAPIES
- S009 THERAPEUTIC HOTLINE
- F042 SO MANY BIOLOGICS, SO LITTLE TIME: HOW TO PICK YOUR POISON IN AN ERA OF BIOLOGIC OVERLOAD.

# SUMMARY

#AAD2019

*Highlights*  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- New topical treatments
- News on already known systemic treatments

# NEWS ON TOPICAL TREATMENTS


Highlights  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- Development of topical treatments blocking ROR-gamma-t that is involved in Th17 cell differentiation.
- No data on efficacy



# NEW COMBINATIONS OR VEHICLES


Highlights  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- New combination of tazarotene 0.045% + halobetasol 0.01% lotion
  - Linda Stein Gold et al. 2019 Winter meeting AAD, Washington.
- New vehicle MC2-01 cream , with higher treatment success than Ca/B TS.
  - Based on PADTm Technology, a patented technology. Oil in water but with a 30 fold fewer surfactants in order to increase tolerance.



# NEWS IN APPROVED DRUGS


Highlights  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★

- BRODALIMUMAB
  - Comments on his potential as it blocks different IL17 through the receptor blockage.



# NEWS IN APPROVED DRUGS. GENETIC MODIFICATION

#AAD2019

*Highlights*  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019


★ WASHINGTON ★

- IL-17 inhibitors. Seem to reverse more dysregulated genes.
- Comparison between IXEKIZUMAB and ETANERCEPT.



# FUMARATES

- Real world evidence. BADBIR
  - PASI 75: 28% at 6 months; 42% at 12 months
    - Ojo 47% de patients continued on FAE for >12 months. .
  - Only 18 % maintained PASI 75 at 6-12 months.



- Commentaries on PASI 75 with guselkumab
  - Guselkumab 90% vs fumarates 27% in week 24 (NRI) with curves that appear to plateaued (different from FAE vs IXE at week 24)

# GUSELKUMAB

#AAD2019

*Highlights*  
**AEDV**  
IN 77<sup>TH</sup> AAD CONGRESS  
1-5 MARCH 2019  
★ WASHINGTON ★

- VOYAGE 2.
  - NRI data PASI 90 through week 72 if PASI 90 was achieved at w28. 86% if continued therapy 36.8% at w48 and 11.5% at week 72. Recapture achieves response in up to 87.6%.
- VOYAGE 1. GUS vs ADA
  - PASI 75 week 16; 91.2 vs 73.1 and w48 87.8 vs 62.6.
  - PASI 90 week 16, 73.3% vs 49.3% and w48 76.3 vs 47.9%.
  - PASI 100 w 37.4 vs 17.1 and w 48 47.4 vs 23.4

# TILDRAKIZUMAB


Highlights  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS


1-5 MARCH 2019

★ WASHINGTON ★

- TILDRAKIZUMAB reSURFACE 1 and 2 pooled analysis long term 100 mg at week 148. 91.2% PASI 75 and 67.6% PASI 90
- MIRIKIZUMAB.
  - PASI 90 at week 16. 67 with 300 mg and 59 with 100 mg.
  - PASI 90 at week 52 if PASI 90 was not achieve at w 16. 60%. Increased in the other groups as they changed from previous dose to 300 mg.



**PASI 90 response among PASI 90 nonresponders at Week 16**



# RISANKIZUMAB

Highlights  
**AEDV**

IN 77<sup>TH</sup> AAD CONGRESS


1-5 MARCH 2019

★ WASHINGTON ★


- ultiMMA 1 and 2. PASI 90 through week 52.
- In whose achieving PASI 90 a w16 (NRI) 88.4% vs 73.3%.

## PASI 90 response over 52 weeks (NRI):

### ultiMMA-1



## PASI 100 at Week 16 (NRI)





# CERTOLIZUMAB PEGOL




IN 77<sup>TH</sup> AAD CONGRESS

1-5 MARCH 2019

★ WASHINGTON ★


## CIMPASI-1, CIMPASI-2, and CIMPACT: Durability of response with certolizumab pegol over 48 weeks

PASI responses among Week 16 PASI 75 responders




		CYP 200 mg q2w	CYP 400 mg q2w
Week 48	MCMC, %	86.1	98.0
	NRI, %	79.2	91.7

PASI 90 responses among Week 16 PASI 90 responders



		CYP 200 mg q2w	CYP 400 mg q2w
Week 48	MCMC, %	64.7	77.4
	NRI, %	60.1	73.3



		CYP 200 mg q2w	CYP 400 mg q2w
Week 48	MCMC, %	80.1	89.0
	NRI, %	75.0	84.5